Gain Therapeutics FY2025 net loss $20.2M ($0.61/sh); cash $20.8M; Phase 1b data supports GT-02287

Gain Therapeutics, Inc.

Net loss $20.2M ($0.61 per share) vs $20.4M ($0.89) prior year; R&D $10.2M, G&A $8.5M.
Cash, equivalents & marketable securities $20.8M as of Dec 31, 2025 (up from $10.4M).
Phase 1b extension: 14 of 16 participants completed day 150; MDS-UPDRS scores stable.
CSF GluSph decreased 81% at day 90 in elevated-baseline participants; DDC also reduced.
IND submission for GT-02287 expected 2Q26; Phase 2 start 3Q26; Phase 1b final data 4Q26.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Gain Therapeutics, Inc. reported year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $20.2 million, or $0.61 per share, basic and diluted, EPS $0.61 per share, basic and diluted.

Period: year ended December 31, 2025
Net income: Net loss for the year ended December 31, 2025, was $20.2 million, or $0.61 per share, basic and diluted
EPS: $0.61 per share, basic and diluted
Result: reported results

Exact text from the filing

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update BETHESDA, MD, March 26, 2026 -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-035174

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.